Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
9 Cards in this Set
- Front
- Back
|
A patient is identified as having stage 2 Alzheimer's disease and elects to take donepezil, Aricept. The patient asks the NP how long the medication will be needed. The NP should tell the patient that donepezil be taken |
Indefinitely because it is not Curative. Cholinesterase inhibitor drugs such as donepezil diminish symptoms, when the drug is stopped, the symptoms returned. Cognitive function will show Improvement at about 24 weeks, but the drug must be continued indefinitely |
|
|
A patient who has Alzheimer's disease has been taking donepezil for 1 year. The patient's spouse reports a worsening of symptoms. The NP should considerr |
Adding memantine hydrochloride, Namenda. This can be added to therapy when symptoms worsen. Ginkgo biloba may be useful but is not recommended as adjunct therapy. Antidepressants given to patients with Alzheimer's disease who have depression appear not to be effective and often cause adverse effects or produce unwanted drug interactions. Galantamine is part of first-line therapy but should not be given with the nausea pill because both are che, cholinesterase inhibitors |
|
|
Early-stage Alzheimer's disease is diagnosed in a patient, and the NP recommends therapy with a che inhibitor. The patient asks why drug treatment is necessary because most functioning is intact. The NP should explain that medication May |
Delay progression of symptoms. Pharmacologic treatment should begin as soon as Alzheimer's disease is suspected because early treatment can slow disease progression. Medication does not produce disease remission or prevent depression. Disease eventually progresses despite medication and a drug therapies are often required |
|
|
A patient has a diagnosis of depression and Alzheimer's disease with mild intermittent symptoms. The NP should prescribe |
Cholinesterase inhibitor. Antidepressants given to patients with Alzheimer's disease do not appear to be effective and cause adverse effects and unwanted drug interactions |
|
|
A patient who has Alzheimer's disease begins taking donezipil, Aricept. After three months of treatment, the patient does not show Improvement of symptoms. The NP should |
Continue donepezil and re-evaluate in 3 months. Patients should be switch to another medication if initial therapy fails, but switching to another medication should be considered only after a minimum of six months of treatment |
|
|
A patient is newly diagnosed with Alzheimer's disease stage 6 on the global deterioration scale. The NP should prescribe |
Memantine Namenda. Patients with moderate to severe dementia, stages 5 to 7, Maybe started on this drug |
|
|
A patient has been taking donepezil, Aricept for several months after being diagnosed with Alzheimer's disease. The patient's spouse brings the patient to the clinic and reports that the patient seems to be having visual hallucinations. The NP should |
Decrease the dose. Hallucinations may be a sign of drug toxicity. The NP should decrease the dose |
|
|
A patient who has Alzheimer's disease is taking 10 mg of donepezil daily and reports difficulty sleeping. The NP should recommend |
Taking the drug in the morning. Donepezil is typically taken in the evening just before going to bed, however, in patients experiencing sleep disturbance, daytime Administration is preferred. The dose should not be increased or decreased |
|
|
A patient who is diagnosed with Alzheimer's disease experiences visual hallucinations. The NP should initially prescribed |
Revastigmine, Exelon. Patients with dementia with Lewy bodies may show benefit with rivastigmine. Visual hallucinations are Hallmark feature of Lewy Body dementia |
